 |
 Rajeev joined SR One in 2003 and is an alum of the Kauffman Fellows Program. He serves as a director on the board of Nucleonics and is an observer on the board of CyDex Pharmaceuticals. Rajeev has also been involved with SR One’s investments in Trigen, Hypnion, Predix Pharmaceuticals, Rib-X Pharmaceuticals, Octoplus, Linguagen, Pinnacle Pharmaceuticals and Point Biomedical. In addition to his role at SR One, Rajeev spent time with the Competitive Excellence group within GSK working on company-wide strategic projects for GSK’s Corporate Executive Team. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development. He was a member of the Chemistry, Manufacture and Controls (CMC) team responsible for the clinical development of Raptiva. Before Genentech, Rajeev worked in a product development role at Bio-Rad Laboratories exploring "lab-on-a-chip" technologies. In addition, Rajeev has worked at Genome Therapeutics in the business development group and at the NJTC Venture Fund. Rajeev was a co-founder of Unimicro Technologies, a company that was created to develop and commercialize instrumentation for biomedical analysis. He holds an MBA degree from the Wharton School of the University of Pennsylvania, a PhD degree in Chemistry from Stanford University, and a BA degree in Chemistry and Mathematics from Knox College. |
2008 SR One Ltd